Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

The First Cell Culture Platform that Enables Affordable Cell Therapies at a Large Scale

Descrizione del progetto

Offrire al mondo una terapia cellulare economica

Nella lotta contro malattie quali il cancro o il diabete, la terapia cellulare è emersa come nuovo trattamento rivoluzionario. Essa prevede la somministrazione ai pazienti di cellule, a volte modificate, che si configurano come specifiche per la malattia in questione. I principali ostacoli a un’adozione e un trattamento diffusi sono i costi e la disponibilità, data la necessità di infrastrutture e specialisti per mettere in atto questa terapia. Superando tali ostacoli, l’azienda Aglaris, che ha sede nel Regno Unito, ha sviluppato la prima piattaforma di coltura cellulare completamente autonoma. Avendo già dimostrato l’efficacia della piattaforma, il progetto Facer, finanziato dall’UE, si prefigge di finalizzare il prodotto e di assicurarsi collaborazioni per immetterlo su un mercato più ampio. Questa soluzione innovativa offrirà una terapia cellulare economica e aiuterà i pazienti in tutto il mondo a lottare contro gravi malattie in precedenza incurabili.

Obiettivo

Cell therapy has shown promising results for treating and curing a large range of diseases, from cancer to diabetes. The principles of cell therapy are easy to describe: cells (possibly modified) are injected into patients. Cell therapy is now a reality in Europe: in August 2018 the first two treatments for patients with blood cancer were approved; more of them are about to successfully conclude the approval path. What hinders the large-scale uptake of cell therapy is its costs: culturing enough cells of high quality requires specialised personnel and infrastructure, which only a few centres can afford. The market asks for a scalable cell culture platform that can produce large quantities of high quality cells at much lower costs than done nowadays. To address this need, we have developed the Facer – the first fully-autonomous cell culture platform. The Facer can manufacture billions of high-quality cells starting from the small quantity (about 500,000 cells) of a tissue biopsy without the need of human intervention, thanks to a unique patented iterative process. Our product is at TRL 7; its performances, in terms of quality and costs, are superior to any competitor commercially available. We have developed the Facer over the course of 5 years thanks to cash investments of over €3 million. In the Phase 2 project we will finalise the product, perform a validation with external partners, prepare the product for CE marking (our product is not a medical device), and find a distributor and a launching customer. We will initially tackle the European market to then expand globally once that the local regulatory barriers are overcome. In 2024, after 5 years from the first sale, our turnover will surpass the €60 million and our EBITDA will be over €36 million. Our innovation can enable affordable cell therapies at a large scale and change the life of millions of patients who suffer from diseases that have been deemed 'incurable' so far.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

SME-2 - SME instrument phase 2

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-EIC-SMEInst-2018-2020

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

AGLARIS LIMITED
Contributo netto dell'UE
€ 1 435 700,00
Indirizzo
STEVENAGE BIOSCIENCE CATALYST, F30, GUNNELS WOOD R
SG1 2FX Stevenage
Regno Unito
PMI
Sì
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 2 051 000,00